|
Additionally, a live webcast and replay will be available under the Events and Presentations section of Terran Orbital's investor relations website at Terran Orbital Corporation Events & ...
01Net
-
11-5-2024
|
|
|
|
Improved AI Remediation Kondukto's AI Remediation capabilities have been available in production for over a year and customers have been able to cut down on meant - time - to - resolution since. Now ...
01Net
-
10-5-2024
|
|
|
|
Additional information concerning Douglas Elliman Realty is available on its website, www.elliman.com . Investors and others should note that we may post information about Douglas Elliman Inc. on our ...
01Net
-
10-5-2024
|
|
|
|
Additional information is available at windstream.com . Follow us on X (Twitter) @Windstream . Category: Corporate Contacts Windstream Contact Scott Morris, 501 - 748 - 5342 scott.l.morris@windstream.
01Net
-
10-5-2024
|
|
|
|
... reconciliations of adjusted EBITDA and pro forma adjusted diluted earnings per share guidance to the closest corresponding GAAP measure on a forward - looking basis is not available without ...
01Net
-
10-5-2024
|
|
|
|
A reconciliation of non - GAAP outlook measures to corresponding GAAP measures is not available on a forward - looking basis without unreasonable effort due to the uncertainty regarding, and the ...
01Net
-
10-5-2024
|
|
|
|
'Our comprehensive platform access is now available to all K - 12 schools at no cost, allowing them to budget for targeted intervention with best - in - class high - dosage tutoring options, ...
01Net
-
10-5-2024
|
|
|
|
A 30 - day online replay will be available approximately one hour following the conclusion of the live webcast. To listen to the live webcast or access the replay, visit the Company's investor ...
01Net
-
10-5-2024
|
|
|
|
... I am excited about our future.' Prior to the earnings conference call a presentation titled 'DNOW First Quarter 2024 Key Takeaways' will be available on the Company's Investor Relations website. ...
01Net
-
10-5-2024
|
|
|
|
WGc - 043 has already completed investigator - initiated trials (IIT) in NPC and NKTL, demonstrating superior safety and efficacy compared to other publicly available mRNA therapeutic cancer vaccines.
Adnkronos
-
10-5-2024
|
|
|
